Literature DB >> 9880552

Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.

R A McKay1, L J Miraglia, L L Cummins, S R Owens, H Sasmor, N M Dean.   

Abstract

The use of antisense oligonucleotides to inhibit the expression of targeted mRNA sequences is becoming increasingly commonplace. Although effective, the most widely used oligonucleotide modification (phosphorothioate) has some limitations. In previous studies we have described a 20-mer phosphorothioate oligodeoxynucleotide inhibitor of human protein kinase C-alpha expression. In an effort to identify improved antisense inhibitors of protein kinase C expression, a series of 2' modifications have been incorporated into the protein kinase C-alpha targeting oligonucleotide, and the effects on oligonucleotide biophysical characteristics and pharmacology evaluated. The incorporation of 2'-O-(2-methoxy)ethyl chemistry resulted in a number of significant improvements in oligonucleotide characteristics. These include an increase in hybridization affinity toward a complementary RNA (1.5 degrees C per modification) and an increase in resistance toward both 3'-exonuclease and intracellular nucleases. These improvements result in a substantial increase in oligonucleotide potency (>20-fold after 72 h). The most active compound identified was used to examine the role played by protein kinase C-alpha in mediating the phorbol ester-induced changes in c-fos, c-jun, and junB expression in A549 lung epithelial cells. Depletion of protein kinase C-alpha protein expression by this oligonucleotide lead to a reduction in c-jun expression but not c-fos or junB. These results demonstrate that 2'-O-(2-methoxy)ethyl-modified antisense oligonucleotides are 1) effective inhibitors of protein kinase C-alpha expression, and 2) represent a class of antisense oligonucleotide which are much more effective inhibitors of gene expression than the widely used phosphorothioate antisense oligodeoxynucleotides.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9880552     DOI: 10.1074/jbc.274.3.1715

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Linear 2' O-Methyl RNA probes for the visualization of RNA in living cells.

Authors:  C Molenaar; S A Marras; J C Slats; J C Truffert; M Lemaître; A K Raap; R W Dirks; H J Tanke
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

2.  Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth.

Authors:  J Chen; W Wu; S K Tahir; P E Kroeger; S H Rosenberg; L M Cowsert; F Bennett; S Krajewski; M Krajewska; K Welsh; J C Reed; S C Ng
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

Review 3.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

4.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

Authors:  Kyle W Sloop; Julia Xiao-Chun Cao; Angela M Siesky; Hong Yan Zhang; Diane M Bodenmiller; Amy L Cox; Steven J Jacobs; Julie S Moyers; Rebecca A Owens; Aaron D Showalter; Martin B Brenner; Achim Raap; Jesper Gromada; Brian R Berridge; David K B Monteith; Niels Porksen; Robert A McKay; Brett P Monia; Sanjay Bhanot; Lynnetta M Watts; M Dodson Michael
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

5.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

6.  Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells.

Authors:  Matthew C Catley; Joanna E Chivers; Neil S Holden; Peter J Barnes; Robert Newton
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

7.  3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA.

Authors:  Jeremy E Wilusz; Susan M Freier; David L Spector
Journal:  Cell       Date:  2008-11-28       Impact factor: 41.582

8.  Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis.

Authors:  Tien-Phat V Huynh; Fan Liao; Caroline M Francis; Grace O Robinson; Javier Remolina Serrano; Hong Jiang; Joseph Roh; Mary Beth Finn; Patrick M Sullivan; Thomas J Esparza; Floy R Stewart; Thomas E Mahan; Jason D Ulrich; Tracy Cole; David M Holtzman
Journal:  Neuron       Date:  2017-12-06       Impact factor: 17.173

9.  Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line.

Authors:  Lauren R Moore; Laura Keller; David D Bushart; Rodrigo G Delatorre; Duojia Li; Hayley S McLoughlin; Maria do Carmo Costa; Vikram G Shakkottai; Gary D Smith; Henry L Paulson
Journal:  Stem Cell Res       Date:  2019-07-16       Impact factor: 2.020

10.  Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.

Authors:  Hayley S McLoughlin; Lauren R Moore; Ravi Chopra; Robert Komlo; Megan McKenzie; Kate G Blumenstein; Hien Zhao; Holly B Kordasiewicz; Vikram G Shakkottai; Henry L Paulson
Journal:  Ann Neurol       Date:  2018-08-06       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.